Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

Specialists complete first procedure in historic head-to-head TAVR study

The global trial is designed to compare TAVR systems from Medtronic and Edwards Lifesciences when treating patients with small annuli.

Abbott’s next-generation device for tricuspid heart valve repair gains CE mark approval

The device is only approved in the United States for investigational use at this time.

Thumbnail

New guidelines focus on the management of heart failure patients with secondary mitral regurgitation

The Heart Failure Association, European Association of Cardiovascular Imaging, European Heart Rhythm Association and European Association of Percutaneous Cardiovascular Interventions all collaborated on the position statement.

Thumbnail

What TAVR availability has meant for patients with severe aortic stenosis

The impact on patients over the age of 65 has been undeniable. 

Thumbnail

TMVR safe and effective for kidney transplant recipients

One important detail, however, was that acute kidney injury was more common for kidney transplant recipients. The researchers listed numerous potential explanations for this trend.

‘A new treatment option’: FDA approves Harmony TPV, says it could delay the need for certain surgeries

The solution’s approval was based on 30-day and six-month data from a clinical study focused on mortality and hemodynamic function.

Thumbnail

TMVR for pediatric patients: ‘Acutely effective and safe, with very encouraging results’

The analysis included eight consecutive pediatric patients who underwent TMVR with the Sapien S3 valve. The median patient age was 9 years old. 

Thumbnail

How heart rhythm issues affect 2-year TAVR, SAVR outcomes

The study’s authors explored data from more than 900 low-risk patients who participated in the PARTNER 3 trial.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.